.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Analyze global market entry opportunities
  • Identify first generic entrants

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

UBS
Boehringer Ingelheim
Dow
Farmers Insurance
Deloitte
Chinese Patent Office
Johnson and Johnson
AstraZeneca
Federal Trade Commission
Cantor Fitzgerald

Generated: July 21, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,829,530

« Back to Dashboard

Details for Patent: 7,829,530

Title:Method of regulating glucose metabolism, and reagents related thereto
Abstract: One aspect of the present invention relates to a method for treating Type II diabetes in an animal, comprising conjointly administering to the animal metformin and an inhibitor of dipeptidylpeptidase IV or a pharmaceutically acceptable salt thereof in an amount sufficient to treat Type II diabetes of the animal but not sufficient to suppress the animal's immune system.
Inventor(s): Bachovchin; William W. (Cambridge, MA), Plaut; Andrew G. (Lexington, MA), Drucker; Daniel (Toronto, CA)
Assignee: Trustees of Tufts College (Medford, MA) New England Medical Center Hospitals (Boston, MA) 1149336 Ontario, Inc. (Toronto, ON, unknown)
Filing Date:Nov 26, 2008
Application Number:12/323,751
Claims:1. A method for treating type II diabetes in an animal, comprising conjointly administering to the animal (i) metformin, and (ii) an inhibitor of dipeptidylpeptidase IV represented in the general formula: ##STR00039## or a pharmaceutically acceptable salt thereof, wherein R.sub.1 represents a C-terminally linked amino acid residue or amino acid analog, or a C-terminally linked peptide or peptide analog, or ##STR00040## R.sub.6 represents hydrogen, a halogen, an alkyl, an alkenyl, an alkynyl, an aryl, --(CH.sub.2).sub.m--R.sub.7, --(CH.sub.2).sub.m--OH, --(CH.sub.2).sub.m-O-alkyl, --(CH.sub.2).sub.m--O-alkenyl, --(CH.sub.2).sub.m--O-alkynyl, --(CH.sub.2).sub.m--O--(CH.sub.2).sub.m--R.sub.7, --(CH.sub.2).sub.m--SH, --(CH.sub.2).sub.m--S-alkyl, --(CH.sub.2).sub.m--S-alkenyl, --(CH.sub.2).sub.m--S-alkynyl, --(CH.sub.2).sub.m--S--(CH.sub.2).sub.m--R.sub.7, ##STR00041## R.sub.7 represents an aryl, a cycloalkyl, a cycloalkenyl, or a heterocycle; R.sub.8 and R.sub.9 each independently represent hydrogen, alkyl, alkenyl, --(CH.sub.2).sub.m--R.sub.7, --C(.dbd.O)-alkyl, --C(.dbd.O)-alkenyl, --C(.dbd.O)-alkynyl, --C(.dbd.O)--(CH.sub.2), --R.sub.7, or R.sub.8 and R.sub.9 taken together with the N atom to which they are attached complete a heterocyclic ring having from 4 to 8 atoms in the ring structure; R.sub.11 and R.sub.12 each independently represent hydrogen, an alkyl, or a pharmaceutically acceptable salt, or R.sub.11 and R.sub.12 taken together with the O--B--O atoms to which they are attached complete a heterocyclic ring having from 5 to 8 atoms in the ring structure; m is zero or an integer in the range of 1 to 8; and n is an integer in the range of 1 to 8, and wherein the inhibitor inhibits dipeptidylpeptidase proteolysis of GLP-1 with a Ki of less than about 10 nM, wherein the metformin and inhibitor are administered in an amount sufficient to treat Type II diabetes but not sufficient to suppress the immune system of the animal.

2. The method of claim 1, wherein said conjointly administering is achieved by separate dosing of the metformin and inhibitor.

3. The method of claim 1, wherein said conjointly administering is achieved by administering the metformin and inhibitor in the same composition.

4. The method of claim 2 or 3, wherein the inhibitor has a Ki for inhibition of dipeptidylpeptidase proteolysis of GLP-1 of 1.0 nm or less.

5. The method of claim 1, 2 or 3, wherein the inhibitor has a molecular weight less than 7500 amu.

6. The method of claim 1, 2 or 3, wherein the metformin and the inhibitor are administered orally.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cerilliant
Daiichi Sankyo
Cantor Fitzgerald
Colorcon
Merck
Argus Health
Express Scripts
McKinsey
Federal Trade Commission
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot